Thus, understanding the molecular mechanisms underlying the expression of DNAM-1 ligands on MM cells is crucial for the development of therapeutic approaches aimed at rendering these cancer cells more susceptible to recognition and killing by NK cells [30]. The gene discussed is CD226; the disease is Miyoshi myopathy.